RAUL VERA-GIMON
Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology KISSIMMEE, FL NPI 1770143752
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology FL PFIZER INC. All categories
General Payments — all program years on this page
$2,416.86
- Category: General Payments
- Program years: PY2021–2024
- Record count: 113
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,400.55 across 66 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,400.55 | 66 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $220.90 | 14 |
| Merck Sharp & Dohme Corporation | $161.68 | 7 |
| Celgene Corporation | $133.95 | 5 |
| Incyte Corporation | $112.82 | 6 |
| Acerta Pharma LLC | $84.27 | 4 |
| SOBI, INC | $79.65 | 3 |
| Lilly USA, LLC | $72.83 | 3 |
| GENZYME CORPORATION | $61.24 | 2 |
| Bayer HealthCare Pharmaceuticals Inc. | $54.08 | 3 |
| Daiichi Sankyo Inc. | $45.10 | 2 |
| Genentech USA, Inc. | $44.00 | 2 |
| GlaxoSmithKline, LLC. | $40.51 | 2 |
| Janssen Biotech, Inc. | $39.80 | 2 |
| ABBVIE INC. | $34.49 | 1 |
| EMD Serono, Inc. | $34.40 | 2 |
| Sumitomo Pharma America, Inc. | $27.95 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $26.08 | 1 |
| Gilead Sciences, Inc. | $25.78 | 1 |
| Stemline Therapeutics Inc. | $24.35 | 1 |
| Alexion Pharmaceuticals, Inc. | $21.92 | 1 |
| Blueprint Medicines Corporation | $20.00 | 1 |
| Mirati Therapeutics, Inc. | $17.86 | 1 |
| JAZZ PHARMACEUTICALS INC. | $16.89 | 1 |
By program year
Records — PY2024 (66)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.